Woolhouse M E
Department of Zoology, University of Oxford, UK.
Vaccine. 1995 Aug;13(12):1045-50. doi: 10.1016/0264-410x(95)00083-d.
The potential outcomes of a Phase II schistosomiasis vaccine trial are explored using mathematical models which assume some natural immunity and a vaccine providing partial protection for a limited time. Analyses suggest that vaccination may have only a limited impact on life-long cumulative worm burdens and may lead to increased susceptibility and higher worm burdens at some ages, a "rebound" effect which results reduced opportunity to acquire natural immunity. There is a trade-off between the degree and duration of vaccine-induced protection; long-lived vaccines may be preferable to vaccines giving greater protection but for a shorter time.